<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896912440820</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896912440820</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Do Adventitial Mast Cells Contribute to the Pathogenesis of Ascending Thoracic Aorta Aneurysm?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Anvari</surname><given-names>Maryam Sotoudeh</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boroumand</surname><given-names>Mohammad Ali</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mojarad</surname><given-names>Elham Ameli</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karimi</surname><given-names>Abbasali</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Abbasi</surname><given-names>Kyomars</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shirzad</surname><given-names>Mahmood</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Omran</surname><given-names>Abbas Salehi</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Movahedi</surname><given-names>Namvar</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shirani</surname><given-names>Shapour</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goodarzynejad</surname><given-names>Hamidreza</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912440820">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896912440820"><label>1</label>Tehran University of Medical Sciences, Tehran, Iran</aff>
<author-notes>
<corresp id="corresp1-1066896912440820">Maryam Sotoudeh Anvari, Department of Surgical and Clinical Pathology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Street, Tehran 1411713138, Iran Email: <email>maryamsotoudeh2006@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>5</issue>
<fpage>474</fpage>
<lpage>479</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The precise pathogenesis of the ascending aortic aneurysm (AscAA) remains to be determined. Mast cells in the adventitia of human AscAA lesions may play a role in this pathogenesis. Adventitial mast cell density per 10 high-power fields (0.25 mm<sup>2</sup>) was assessed in multiple biopsy samples, from aneurysmal aortic sections (n = 41) and control (nondilated) aortic specimens (n = 50), stained by orcein-Giemsa method, an inexpensive (&lt;$1) method. In a multivariable adjusted logistic regression model, using AscAA as the dependent variable, mast cell density was found to be an independent predictor of AscAA occurrence (odds ratio = 2.21; 95% confidence interval = 1.58-3.08; <italic>P</italic> &lt; .001). Receiver operating characteristic curve analysis showed that the proposed cutoff value of ≥3 mast cells per 10 high-power fields was very sensitive to detect AscAA occurrence, yielding a sensitivity of 90% with a specificity of 80%. In conclusion, a significant increase in the number of mast cells in the adventitia of human ascending aortic lesions proposes a role for these cells in the pathogenesis of AscAA.</p>
</abstract>
<kwd-group>
<kwd>mast cell</kwd>
<kwd>adventitia</kwd>
<kwd>inflammation</kwd>
<kwd>aneurysm</kwd>
<kwd>ascending aorta</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896912440820" sec-type="intro">
<title>Introduction</title>
<p>Mast cells are bone marrow–derived inflammatory cells that when activated can release several potent mediators from within their granules, many of which are considered to be proinflammatory and also able to promote the local degradation or remodeling of structural elements of tissues influenced by inflammatory responses. Such alterations in tissues may be associated with significant changes in the functioning of the affected organs.<sup><xref ref-type="bibr" rid="bibr1-1066896912440820">1</xref><xref ref-type="bibr" rid="bibr2-1066896912440820"/>-<xref ref-type="bibr" rid="bibr3-1066896912440820">3</xref></sup> Increased numbers of mast cells at the sites of chronic inflammation have been observed during light microscopic examinations for more than a century.<sup><xref ref-type="bibr" rid="bibr4-1066896912440820">4</xref></sup> Currently, there is a long list of conditions in which greater numbers of mast cells are reported to be seen.<sup><xref ref-type="bibr" rid="bibr4-1066896912440820">4</xref></sup></p>
<p>On the other hand, mast cells express products such as IL-10 and TGF-β, which are known to have “anti-inflammatory” effects.<sup><xref ref-type="bibr" rid="bibr5-1066896912440820">5</xref>,<xref ref-type="bibr" rid="bibr6-1066896912440820">6</xref></sup> Thus, it is difficult to predict how mast cell activation will influence chronic inflammation or other types of biological responses, and the possible detrimental or beneficial effects of mast cell accumulation in tissues is debatable.</p>
<p>Aortic aneurysm development is a chronic degenerative and inflammatory disease, which is characterized by weakening and dilation of the aortic wall, resulting in a life-threatening risk of rupture.<sup><xref ref-type="bibr" rid="bibr7-1066896912440820">7</xref></sup> The frequency of abdominal aortic aneurysms (AAAs) located in the infrarenal section of the aorta is at least 3 times higher than that of thoracic aortic aneurysms (TAAs). In TAAs, one or more aortic segments, including aortic root, ascending aorta, arch, or descending aorta, may be involved, based on which it is classified. Sixty percent of TAAs involve the aortic root and/or the ascending aorta aneurysm (AscAA).<sup><xref ref-type="bibr" rid="bibr8-1066896912440820">8</xref></sup> Important differences exist in pathology related to these 2 types of aneurysms (AAA vs AscAA). In contrast to the abdominal aorta, atherosclerosis rarely presents in the ascending aorta.</p>
<p>Although several investigations have aimed to identify the pathogenesis of the aortic aneurysm, the precise pathogenesis of the disease remains to be determined. Based on the pathophysiology, prevalence, and other features, it is reasonable to postulate that AscAAs and AAAs are distinct disease entities.</p>
<p>Recently, Tsuruda et al<sup><xref ref-type="bibr" rid="bibr9-1066896912440820">9</xref></sup> suggested that adventitial mast cells contribute to the formation of abdominal aneurysm. To our knowledge, no previous study has examined the potential role of mast cells in the pathogenesis of AscAA; thus, the aim of the present study was quantification of mast cells in the adventitia of human AscAA lesions.</p>
</sec>
<sec id="section2-1066896912440820" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>From April 2007 to April 2010, excluding those with Marfan syndrome (n = 5), with atheromatous plaques in the ascending aorta (n = 3), and with previous history of allergic diseases such as asthma, allergic rhinitis, sinusitis, urticaria, inflammatory vasculitis, and aortitis, all consecutive patients who underwent Bentall operation for repair of aortic aneurysm at our center enrolled in the study. Human AscAA sections were excised from every 1 cm of AscAA lesions in patients undergoing aneurysm repair surgery (n = 41). Nondilated control aortic samples were obtained from multiple (ranging from 3 to 7) punch-biopsy specimens of the ascending aorta from each patient in the control group, namely, patients without AscAA lesions undergoing coronary artery bypass graft surgery in the same time period (n = 50).</p>
<p>Specimens were processed for routine histologic examination with 10% buffered formalin as fixative and were paraffin embedded. Sections were microscopically assessed using hematoxylin and eosin, orcein-Giemsa, and trichrome stains. Using a standard light microscope (YS100, Nikon, Belmont, CA) with an oil-immersion objective (1000× magnification), adventitial mast cells were counted in 10 high-power fields, and the sum was calculated for each section (measuring 0.25 mm<sup>2</sup>). The average of mast cell counts in all related sections in each case or control subject was reported. The aforementioned protocol for taking tissues was approved by the local committee of our hospital, and informed consent was obtained from all patients involved in the study.</p>
<sec id="section3-1066896912440820">
<title>Data Collection</title>
<p>Pathological data were prospectively collected by a single expert pathologist at our center. Then, we merged these prospectively gathered data with the hospital surgery database by using a patient’s file number variable to obtain the patient’s variables, including demographic characteristics, cardiovascular risk factors, type of medications used, existence of thoracic aortic dissection, and aneurysmal size.</p>
</sec>
<sec id="section4-1066896912440820">
<title>Definitions</title>
<p>A positive family history was defined as coronary artery disease in a parent or a sibling younger than 55 years for men and younger than 65 years for women. Patients who smoked any kind of tobacco at the time of study or who had quit smoking for less than 1 month were considered as current smokers. Dyslipidemia was defined as plasma total cholesterol level ≥200 mg/dL, LDL (low-density lipoprotein) cholesterol level ≥130 mg/dL, triglyceride level ≥200 mg/dL, and HDL (high-density lipoprotein) cholesterol level &lt;40 mg/dL, or being on lipid-lowering drugs at the time of study. Patients were considered to have hypertension if they had received a diagnosis with arterial pressure more than 140/90 mm Hg or were being treated with antihypertensive medications. Patients with a history of diabetes, who were on insulin or oral hypoglycemic agents, were considered to have diabetes. In patients with lack of awareness of their past history, diabetes was defined according to the latest World Health Organization criteria.<sup><xref ref-type="bibr" rid="bibr10-1066896912440820">10</xref></sup> Body mass index was calculated as weight (kg) divided by the square of height (m<sup>2</sup>).</p>
</sec>
<sec id="section5-1066896912440820">
<title>Statistical Analyses</title>
<p>Statistical results are expressed as mean ± standard deviation (mean ± SD) for numerical variables and as raw numbers and percentages for categorical variables. Continuous variables were compared using Student’s <italic>t</italic> test, and categorical variables were compared using χ<sup>2</sup> test or Fisher’s exact test as appropriate, across the 2 groups with and without TAA. Kolmogorov–Smirnov test was used to determine whether the data deviated significantly from the normal distribution. Also, to determine the relationship between mast cell density and aneurysmal size, Spearman’s correlation test was applied.</p>
<p>A multivariable logistic regression model for appraising the association between mast cell concentration and TAA, as the dependent variable, accounting for confounding effects of age, male gender, cigarette smoking, hypertension, and dyslipidemia, was constructed. The association was expressed as an odds ratio (OR) with 95% confidence interval (CI). Receiver operating characteristic (ROC) curve analysis was used to identify the mast cell density cutoff point associated with TAA occurrence. For the statistical analyses, the statistical package SAS version 9.1 for windows (SAS Institute Inc, Cary, NC) was used. All <italic>P</italic> values were 2-tailed, with statistical significance defined by <italic>P</italic> ≤ .05.</p>
</sec>
</sec>
<sec id="section6-1066896912440820" sec-type="results">
<title>Results</title>
<p>Baseline clinical characteristics of the patients with and without AscAA are summarized in <xref ref-type="table" rid="table1-1066896912440820">Table 1</xref>. The average age of the study population was 55.79 ± 12.15, ranging from 22 to 79 years. Of the 41 patients with AscAA located in the ascending thoracic aorta, 32 (78.0%) were men and 9 (22.0%) were women. Patients with AscAA were younger and taller and had higher prevalence of diabetes mellitus compared with patients without AscAA, whereas the prevalence of smoking, hypertension, and dyslipidemia was not statistically different between the 2 groups.</p>
<table-wrap id="table1-1066896912440820" position="float">
<label>Table 1.</label>
<caption><p>Baseline Clinical Characteristics of the Study Population<sup><xref ref-type="table-fn" rid="table-fn2-1066896912440820">a</xref></sup></p></caption>
<graphic alternate-form-of="table1-1066896912440820" xlink:href="10.1177_1066896912440820-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">All Patients (n = 91)</th>
<th align="center">Patients With AscAA (n = 41)</th>
<th align="center">Patients Without AscAA (n = 50)</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn3-1066896912440820">b</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55.79 ± 12.15</td>
<td>51.49 ± 13.65</td>
<td>59.32 ± 9.54</td>
<td>.003</td>
</tr>
<tr>
<td>Male gender</td>
<td>70 (76.9)</td>
<td>32 (78.0)</td>
<td>38 (76.0)</td>
<td>.817</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>26.48 ± 4.76</td>
<td>25.55 ± 4.43</td>
<td>27.24 ± 4.93</td>
<td>.093</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74.32 ± 14.68</td>
<td>74.12 ± 13.68</td>
<td>74.48 ± 15.60</td>
<td>.909</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167.47 ± 10.20</td>
<td>170.41 ± 10.56</td>
<td>165.06 ± 9.32</td>
<td>.012</td>
</tr>
<tr>
<td>Current smoker</td>
<td>29 (39.1)</td>
<td>16 (39.0)</td>
<td>13 (26.0)</td>
<td>.185</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>31 (34.1)</td>
<td>15 (36.6)</td>
<td>16 (32.0)</td>
<td>.646</td>
</tr>
<tr>
<td>Hypertension</td>
<td>42 (46.2)</td>
<td>17 (41.5)</td>
<td>25 (50.0)</td>
<td>.416</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>17 (18.7)</td>
<td>4 (9.8)</td>
<td>13 (26.0)</td>
<td>.048</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>39 (42.9)</td>
<td>16 (39.0)</td>
<td>23 (46.0)</td>
<td>.503</td>
</tr>
<tr>
<td colspan="5">Medical therapy</td>
</tr>
<tr>
<td> Statin</td>
<td>53 (58.2)</td>
<td>23 (56.1)</td>
<td>30 (60.0)</td>
<td>.707</td>
</tr>
<tr>
<td> ACE inhibitor</td>
<td>52 (57.1)</td>
<td>21 (51.2)</td>
<td>31 (62.0)</td>
<td>.301</td>
</tr>
<tr>
<td> β-blocker</td>
<td>70 (76.9)</td>
<td>28 (68.3)</td>
<td>42 (84.0)</td>
<td>.077</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896912440820">
<p>Abbreviations: AscAA, ascending aortic aneurysm; ACE, angiotensin-converting enzyme; CAD, coronary artery disease; MI, myocardial infarction.</p>
</fn>
<fn id="table-fn2-1066896912440820">
<label>a</label>
<p>Data are presented as mean ± SD or n (%).</p>
</fn>
<fn id="table-fn3-1066896912440820">
<label>b</label>
<p><italic>P</italic> values for comparing those with and without AscAA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As shown in <xref ref-type="table" rid="table2-1066896912440820">Table 2</xref>, the mean mast cell density was 4.29 ± 0.42 in 0.25 mm<sup>2</sup> (range: 0-16). The mean of adventitial mast cell density in the 41 case subjects was 7.32 ± 0.59 cells per 10 high-power fields as compared with 1.80 ± 0.25 in the control group (<italic>P</italic> &lt; .001; <xref ref-type="fig" rid="fig1-1066896912440820">Figures 1</xref>, <xref ref-type="fig" rid="fig2-1066896912440820">2</xref>, and <xref ref-type="fig" rid="fig3-1066896912440820">3</xref>). In a multivariable logistic regression model, using AscAA as the dependent variable, after controlling for age, male gender, cigarette smoking, hypertension, and dyslipidemia, mast cell density was found to be an independent predictor of AscAA occurrence (OR = 2.21; 95% CI = 1.58-3.08; <italic>P</italic> &lt; .001). However, we found no significant correlation between mast cell density and size of aneurysm in the case group (<italic>r</italic> = −.023, <italic>P</italic> = .890).</p>
<table-wrap id="table2-1066896912440820" position="float">
<label>Table 2.</label>
<caption><p>Characteristics of the Study Population<sup><xref ref-type="table-fn" rid="table-fn5-1066896912440820">a</xref></sup></p></caption>
<graphic alternate-form-of="table2-1066896912440820" xlink:href="10.1177_1066896912440820-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">All Patients (n = 91)</th>
<th align="center">Patients With AscAA (n = 41)</th>
<th align="center">Patients Without AscAA (n = 50)</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn6-1066896912440820">b</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic wall size (mm)</td>
<td align="center">—</td>
<td>58.60 ± 13.34</td>
<td>&lt;30.0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Mast cell density (mean ± SE)</td>
<td>4.29 ± 0.42</td>
<td>7.32 ± 0.59</td>
<td>1.80 ± 0.25</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
<td>103.48 ± 34.76</td>
<td>98.71 ± 35.79</td>
<td>107.40 ± 33.74</td>
<td>.237</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>164.47 ± 88.42</td>
<td>145.61 ± 75.59</td>
<td>179.94 ± 95.68</td>
<td>.065</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>37.05 ± 9.22</td>
<td>38.51 ± 10.36</td>
<td>35.86 ± 8.08</td>
<td>.173</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
<td>94.15 ± 32.23</td>
<td>97.56 ± 33.26</td>
<td>91.35 ± 31.43</td>
<td>.363</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>158.64 ± 43.20</td>
<td>158.51 ± 41.06</td>
<td>158.74 ± 45.29</td>
<td>.980</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>48.97 ± 8.99</td>
<td>49.10 ± 9.59</td>
<td>48.85 ± 8.58</td>
<td>.899</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1066896912440820">
<p>Abbreviations: AscAA, ascending aortic aneurysm; ACE, angiotensin converting enzyme; CAD, coronary artery disease; MI, myocardial infarction; SE, standard error; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction.</p>
</fn>
<fn id="table-fn5-1066896912440820">
<label>a</label>
<p>Data are presented as mean ± SD or n (%) unless otherwise noted.</p>
</fn>
<fn id="table-fn6-1066896912440820">
<label>b</label>
<p><italic>P</italic> values for comparing those with and without AscAA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1066896912440820" position="float">
<label>Figure 1.</label>
<caption>
<p>Adventitial mast cells in nonaneurysm control group (one is seen in this field, 400×, orcein-Giemsa stain)</p>
</caption>
<graphic xlink:href="10.1177_1066896912440820-fig1.tif"/>
</fig>
<fig id="fig2-1066896912440820" position="float">
<label>Figure 2.</label>
<caption>
<p>Adventitial mast cells containing metachromatic granules in aneurysm group (6 are seen in this field, 400×, orcein-Giemsa stain)</p>
</caption>
<graphic xlink:href="10.1177_1066896912440820-fig2.tif"/>
</fig>
<fig id="fig3-1066896912440820" position="float">
<label>Figure 3.</label>
<caption>
<p>Degranulated mast cells containing metachromatic granules (2 are seen in this field, oil immersion 1000×, orcein-Giemsa stain)</p>
</caption>
<graphic xlink:href="10.1177_1066896912440820-fig3.tif"/>
</fig>
<p>Selected cutoff values from the ROC curve analysis with the derived sensitivities, specificities, predictive values, and likelihood ratios are presented in <xref ref-type="table" rid="table3-1066896912440820">Table 3</xref>. Cutoff values with higher positive predictive value and specificity correspond to a lower negative predictive value and sensitivity, and vice versa. The cutoff value was ≥1 when the sensitivity was 100% and the specificity 26%; it was ≥16 when the sensitivity was 2% and specificity 100% (not shown in the table). ROC curve analysis showed that the proposed cutoff value of ≥3 mast cells per 10 high-power fields was very sensitive to detect TAA occurrence, yielding a sensitivity of 90% with a specificity of 80% (<xref ref-type="table" rid="table3-1066896912440820">Table 3</xref>).</p>
<table-wrap id="table3-1066896912440820" position="float">
<label>Table 3.</label>
<caption><p>The Optimal Cutoff Points With Detailed Report of Sensitivity and Specificity Derived From ROC Curve Analysis (Area Under the ROC Curve = 0.9222)</p></caption>
<graphic alternate-form-of="table3-1066896912440820" xlink:href="10.1177_1066896912440820-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Cutoff</th>
<th align="center">Sensitivity (%)</th>
<th align="center">Specificity (%)</th>
<th align="center">PPV (%)</th>
<th align="center">NPV (%)</th>
<th align="center">LR<sup>+</sup></th>
<th align="center">LR<sup>−</sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD ≥ 3</td>
<td>90.2</td>
<td>80.0</td>
<td>78.7</td>
<td>90.9</td>
<td>4.51</td>
<td>0.12</td>
</tr>
<tr>
<td>MCD ≥ 4</td>
<td>85.4</td>
<td>84.0</td>
<td>81.4</td>
<td>87.5</td>
<td>5.34</td>
<td>0.17</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1066896912440820">
<p>Abbreviations: ROC, receiver operating characteristic; PPV, positive predictive value; NPV, negative predictive value; LR<sup>+</sup>, positive likelihood ratio; LR<sup>−</sup>, negative likelihood ratio; MCD, mast cell density.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-1066896912440820" sec-type="discussion">
<title>Discussion</title>
<p>The results of this study revealed that there was a significant quantitative difference among adventitial mast cell counts of patients with ascending aorta aneurysm as compared with the control group. Although mast cell density in adventitia was shown to be an independent predictor of AscAA occurrence, we found no significant correlation between mast cell density and size of aneurysm in the case group. We also found that the frequency of diabetic patients in the aneurysm group was lower than in the control group, despite the fact that diabetes in general has a deleterious impact on the pathogenesis of vascular diseases.</p>
<p>Our results regarding the prevalence of diabetes mellitus in AscAA patients are in line with the findings of many previous studies indicating that diabetes is a negative risk factor for aortic aneurysm.<sup><xref ref-type="bibr" rid="bibr11-1066896912440820">11</xref><xref ref-type="bibr" rid="bibr12-1066896912440820"/>-<xref ref-type="bibr" rid="bibr13-1066896912440820">13</xref></sup> Nonetheless, the precise mechanisms remain to be elucidated. Moreover, the association we found between height and AscAA has been seen in patients with AAA in previous studies even when AAA was defined relative to the suprarenal aorta rather than by unadjusted diameter,<sup><xref ref-type="bibr" rid="bibr14-1066896912440820">14</xref></sup> though to our knowledge no explanation for this relationship has been suggested.</p>
<p>A causal link between mast cell density in the aortic wall and aneurysm rupture was reported by Faleiro et al<sup><xref ref-type="bibr" rid="bibr15-1066896912440820">15</xref></sup> for the first time in 1981. Although the sample size in this study was very limited, the authors demonstrated a more pronounced presence of mast cells in the arteries of Willis circle in patients who died of subarachnoid hemorrhage following aneurysm rupture.<sup><xref ref-type="bibr" rid="bibr15-1066896912440820">15</xref></sup> It was in 1999 that Ihara et al<sup><xref ref-type="bibr" rid="bibr16-1066896912440820">16</xref></sup> conclusively showed the number of activated chymase- and tryptase-positive mast cells to be significantly higher in aneurysmal tissue of human aortas compared with nonaneurysmal atherosclerotic tissue; except for a single case study of a patient who died of coronary artery dissection,<sup><xref ref-type="bibr" rid="bibr17-1066896912440820">17</xref></sup> no study reported on the contribution of mast cells to aneurysm development.</p>
<p>Ejiri et al<sup><xref ref-type="bibr" rid="bibr11-1066896912440820">11</xref></sup> confirmed these findings, at least in part, by revealing that chymase-positive mast cells accumulated in the hypercellular inflammatory regions of TAA tissue samples, where monocytes/macrophages accumulated, suggesting a causal association between the number of activated mast cells and aneurysm rupture. Tsuruda et al<sup><xref ref-type="bibr" rid="bibr18-1066896912440820">18</xref></sup> showed a high number of mast cells in AAA biopsy samples as compared with atherosclerotic aorta tissues without any aneurysmal change. They also found an increased immunoreactivity of these mast cells for adrenomedullin, which exerts antifibrotic actions in cardiovascular remodeling, thereby resulting in reduced stability of the vessel wall.</p>
<p>In their most recent investigation, Tsuruda et al<sup><xref ref-type="bibr" rid="bibr9-1066896912440820">9</xref></sup> have presented a study on both human and rodent samples of AAA.<sup><xref ref-type="bibr" rid="bibr9-1066896912440820">9</xref></sup> Carrying out the study on human samples of AAA, the investigators found that mast cell numbers increased in the aortic adventitia and outer media with progress of atherosclerosis, but a further increase was observed in AAA. They also found a significant correlation between the mast cell count and the maximal diameter of AAA, implying a role for mast cells in the development and progression of AAA.</p>
<p>The investigators also showed that after periaortic application of CaCl<sub>2</sub> in mutant mast cell–deficient (Ws/Ws) and control (+/+) rats, the progressive AAA along with mast cell accumulation and degranulation occurred in the control (+/+) rats but not in the Ws/Ws rats. In addition, accumulation of T-lymphocytes and IFN-γ positive cells and activation of matrix metaloproteinases, MMP-2 and MMP-9, were observed in the control rats but were inhibited in the mast cell–deficient rats.<sup><xref ref-type="bibr" rid="bibr9-1066896912440820">9</xref></sup> Most interestingly, treatment with the mast cell stabilizer agent “tranilast” could block these events.<sup><xref ref-type="bibr" rid="bibr19-1066896912440820">19</xref></sup> This further confirmed the findings of previous studies on the role of adventitial mast cells in the development and progression of AAAs.<sup><xref ref-type="bibr" rid="bibr19-1066896912440820">19</xref><xref ref-type="bibr" rid="bibr20-1066896912440820"/>-<xref ref-type="bibr" rid="bibr21-1066896912440820">21</xref></sup> Mast cells may play a role in AAA pathogenesis by releasing proteases such as chymase and tryptase, by activation of MMPs, by inducing aortic smooth muscle cell apoptosis, and by participating in the inflammatory response and angiogenesis.<sup><xref ref-type="bibr" rid="bibr9-1066896912440820">9</xref>,<xref ref-type="bibr" rid="bibr18-1066896912440820">18</xref>,<xref ref-type="bibr" rid="bibr22-1066896912440820">22</xref><xref ref-type="bibr" rid="bibr23-1066896912440820"/><xref ref-type="bibr" rid="bibr24-1066896912440820"/><xref ref-type="bibr" rid="bibr25-1066896912440820"/>-<xref ref-type="bibr" rid="bibr26-1066896912440820">26</xref></sup> However, the clinical significance of mast cells in the development of AAAs remains to be determined.</p>
<p>On the other hand, there are significant anatomical, histological, and functional differences between the abdominal aorta and the thoracic aorta—and more particularly in the ascending aorta—that are believed to make the thoracic aorta less prone to aneurysm formation.<sup><xref ref-type="bibr" rid="bibr27-1066896912440820">27</xref></sup> Thus, extrapolation of the findings regarding AAAs to TAAs (including AscAAs) is incorrect, though most of our knowledge with regard to the pathobiology of aortic aneurysms comes from studies on AAAs.<sup><xref ref-type="bibr" rid="bibr28-1066896912440820">28</xref><xref ref-type="bibr" rid="bibr29-1066896912440820"/>-<xref ref-type="bibr" rid="bibr30-1066896912440820">30</xref></sup></p>
<p>One limitation of the present study is that immunohistochemistry staining using monoclonal anti-tryptase and anti-chymase antibodies was not applied for detection of mast cell phenotypes. Even though tryptase and chymase are the current “gold standard” for determining mast cell phenotypes in various tissue compartments, orcein-Giemsa staining appears to be another simple, inexpensive (&lt;$1), and readily available diagnostic approach. Moreover, although there are potential regional variations in the presence of mast cells at different levels of the ascending aorta in the control group (eg, at the level of the multiple biopsies vs other areas), we were able to take multiple aortic biopsy specimens from the control group.</p>
<p>In conclusion, the increased number of mast cells in the adventitia of human AscAA lesions suggests a role for these cells in the pathogenesis and progression of AscAA. This new appreciation of the likely role of mast cells in AscAA also raises the question as to whether drugs such as cromolyn sodium antihistamines, used to treat mast cell disease, would be effective in treating or slowing the progression of aortic aneurysm. The quantification of mast cell density in patients with TAA using mast cell count as a dichotomous variable (cutoff point ≥3) may have a role in defining subsets of aortic aneurysm that may be amenable to this therapeutic modality. Further investigations for understanding the underlying mechanisms in the pathogenesis of AscAA and their interrelationship are warranted, to develop therapeutic tools for the clinician.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:</p>
<p>This study was funded by the Tehran Heart Center, Tehran University of Medical Sciences.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896912440820">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>HR</given-names></name>
<name><surname>Pemberton</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut</article-title>. <source>Immunology</source>. <year>2002</year>;<volume>105</volume>:<fpage>375</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr2-1066896912440820">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDermott</surname><given-names>JR</given-names></name>
<name><surname>Bartram</surname><given-names>RE</given-names></name>
<name><surname>Knight</surname><given-names>PA</given-names></name>
<name><surname>Miller</surname><given-names>HR</given-names></name>
<name><surname>Garrod</surname><given-names>DR</given-names></name>
<name><surname>Grencis</surname><given-names>RK</given-names></name>
</person-group>. <article-title>Mast cells disrupt epithelial barrier function during enteric nematode infection</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>:<fpage>7761</fpage>-<lpage>7766</lpage>.</citation>
</ref>
<ref id="bibr3-1066896912440820">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hallgren</surname><given-names>J</given-names></name>
<name><surname>Pejler</surname><given-names>G</given-names></name>
</person-group>. <article-title>Biology of mast cell tryptase. An inflammatory mediator</article-title>. <source>FEBS J</source>. <year>2006</year>;<volume>273</volume>:<fpage>1871</fpage>-<lpage>1895</lpage>.</citation>
</ref>
<ref id="bibr4-1066896912440820">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metz</surname><given-names>M</given-names></name>
<name><surname>Grimbaldeston</surname><given-names>MA</given-names></name>
<name><surname>Nakae</surname><given-names>S</given-names></name>
<name><surname>Piliponsky</surname><given-names>AM</given-names></name>
<name><surname>Tsai</surname><given-names>M</given-names></name>
<name><surname>Galli</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Mast cells in the promotion and limitation of chronic inflammation</article-title>. <source>Immunol Rev</source>. <year>2007</year>;<volume>217</volume>:<fpage>304</fpage>-<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr5-1066896912440820">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galli</surname><given-names>SJ</given-names></name>
<name><surname>Nakae</surname><given-names>S</given-names></name>
<name><surname>Tsai</surname><given-names>M</given-names></name>
</person-group>. <article-title>Mast cells in the development of adaptive immune responses</article-title>. <source>Nat Immunol</source>. <year>2005</year>;<volume>6</volume>:<fpage>135</fpage>-<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr6-1066896912440820">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>MO</given-names></name>
<name><surname>Wan</surname><given-names>YY</given-names></name>
<name><surname>Sanjabi</surname><given-names>S</given-names></name>
<name><surname>Robertson</surname><given-names>AK</given-names></name>
<name><surname>Flavell</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Transforming growth factor-beta regulation of immune responses</article-title>. <source>Annu Rev Immunol</source>. <year>2006</year>;<volume>24</volume>:<fpage>99</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr7-1066896912440820">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem</article-title>. <source>Curr Opin Cardiol</source>. <year>1996</year>;<volume>11</volume>:<fpage>504</fpage>-<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr8-1066896912440820">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isselbacher</surname><given-names>EM</given-names></name>
</person-group>. <article-title>Thoracic and abdominal aortic aneurysms</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>:<fpage>816</fpage>-<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr9-1066896912440820">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsuruda</surname><given-names>T</given-names></name>
<name><surname>Kato</surname><given-names>J</given-names></name>
<name><surname>Hatakeyama</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm</article-title>. <source>Circ Res</source>. <year>2008</year>;<volume>102</volume>:<fpage>1368</fpage>-<lpage>1377</lpage>.</citation>
</ref>
<ref id="bibr10-1066896912440820">
<label>10.</label>
<citation citation-type="book">
<collab>World Health Organization</collab>. <source>Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia</source>. <comment>Report of a WHO consultation</comment>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr11-1066896912440820">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ejiri</surname><given-names>J</given-names></name>
<name><surname>Inoue</surname><given-names>N</given-names></name>
<name><surname>Tsukube</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker</article-title>. <source>Cardiovasc Res</source>. <year>2003</year>;<volume>59</volume>:<fpage>988</fpage>-<lpage>996</lpage>.</citation>
</ref>
<ref id="bibr12-1066896912440820">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lederle</surname><given-names>FA</given-names></name>
<name><surname>Johnson</surname><given-names>GR</given-names></name>
<name><surname>Wilson</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators</article-title>. <source>Arch Intern Med</source>. <year>2000</year>;<volume>160</volume>:<fpage>1425</fpage>-<lpage>1430</lpage>.</citation>
</ref>
<ref id="bibr13-1066896912440820">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>SS</given-names></name>
<name><surname>Littooy</surname><given-names>FN</given-names></name>
<name><surname>Gupta</surname><given-names>SR</given-names></name>
<etal/>
</person-group>. <article-title>Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes</article-title>. <source>Surgery</source>. <year>1999</year>;<volume>126</volume>:<fpage>687</fpage>-<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr14-1066896912440820">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lederle</surname><given-names>FA</given-names></name>
<name><surname>Johnson</surname><given-names>GR</given-names></name>
<name><surname>Wilson</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group</article-title>. <source>Ann Intern Med</source>. <year>1997</year>;<volume>126</volume>:<fpage>441</fpage>-<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr15-1066896912440820">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Faleiro</surname><given-names>LC</given-names></name>
<name><surname>Machado</surname><given-names>CR</given-names></name>
<name><surname>Gripp</surname><given-names>A</given-names><suffix>Jr</suffix></name>
<name><surname>Resende</surname><given-names>RA</given-names></name>
<name><surname>Rodrigues</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Cerebral vasospasm: presence of mast cells in human cerebral arteries after aneurysm rupture</article-title>. <source>J Neurosurg</source>. <year>1981</year>;<volume>54</volume>:<fpage>733</fpage>-<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr16-1066896912440820">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ihara</surname><given-names>M</given-names></name>
<name><surname>Urata</surname><given-names>H</given-names></name>
<name><surname>Kinoshita</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta</article-title>. <source>Hypertension</source>. <year>1999</year>;<volume>33</volume>:<fpage>1399</fpage>-<lpage>1405</lpage>.</citation>
</ref>
<ref id="bibr17-1066896912440820">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saunders</surname><given-names>SL</given-names></name>
<name><surname>Ford</surname><given-names>SE</given-names></name>
</person-group>. <article-title>Primary coronary artery dissection possibly related to drug hypersensitivity in a male</article-title>. <source>Can J Cardiol</source>. <year>1991</year>;<volume>7</volume>:<fpage>138</fpage>-<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr18-1066896912440820">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsuruda</surname><given-names>T</given-names></name>
<name><surname>Kato</surname><given-names>J</given-names></name>
<name><surname>Hatakeyama</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Adrenomedullin in mast cells of abdominal aortic aneurysm</article-title>. <source>Cardiovasc Res</source>. <year>2006</year>;<volume>70</volume>:<fpage>158</fpage>-<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr19-1066896912440820">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J</given-names></name>
<name><surname>Sukhova</surname><given-names>GK</given-names></name>
<name><surname>Wolters</surname><given-names>PJ</given-names></name>
<etal/>
</person-group>. <article-title>Mast cells promote atherosclerosis by releasing proinflammatory cytokines</article-title>. <source>Nat Med</source>. <year>2007</year>;<volume>13</volume>:<fpage>719</fpage>-<lpage>724</lpage>.</citation>
</ref>
<ref id="bibr20-1066896912440820">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bot</surname><given-names>I</given-names></name>
<name><surname>de Jager</surname><given-names>SC</given-names></name>
<name><surname>Zernecke</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>:<fpage>2516</fpage>-<lpage>2525</lpage>.</citation>
</ref>
<ref id="bibr21-1066896912440820">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J</given-names></name>
<name><surname>Sukhova</surname><given-names>GK</given-names></name>
<name><surname>Yang</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice</article-title>. <source>J Clin Invest</source>. <year>2007</year>;<volume>117</volume>:<fpage>3359</fpage>-<lpage>3368</lpage>.</citation>
</ref>
<ref id="bibr22-1066896912440820">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakae</surname><given-names>S</given-names></name>
<name><surname>Suto</surname><given-names>H</given-names></name>
<name><surname>Kakurai</surname><given-names>M</given-names></name>
<name><surname>Sedgwick</surname><given-names>JD</given-names></name>
<name><surname>Tsai</surname><given-names>M</given-names></name>
<name><surname>Galli</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Mast cells enhance T cell activation: Importance of mast cell-derived TNF</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>:<fpage>6467</fpage>-<lpage>6472</lpage>.</citation>
</ref>
<ref id="bibr23-1066896912440820">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lohi</surname><given-names>J</given-names></name>
<name><surname>Harvima</surname><given-names>I</given-names></name>
<name><surname>Keski-Oja</surname><given-names>J</given-names></name>
</person-group>. <article-title>Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin</article-title>. <source>J Cell Biochem</source>. <year>1992</year>;<volume>50</volume>:<fpage>337</fpage>-<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr24-1066896912440820">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leskinen</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Leszczynski</surname><given-names>D</given-names></name>
<name><surname>Lindstedt</surname><given-names>KA</given-names></name>
<name><surname>Kovanen</surname><given-names>PT</given-names></name>
</person-group>. <article-title>Mast cell chymase induces apoptosis of vascular smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2001</year>;<volume>21</volume>:<fpage>516</fpage>-<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr25-1066896912440820">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koullias</surname><given-names>GJ</given-names></name>
<name><surname>Ravichandran</surname><given-names>P</given-names></name>
<name><surname>Korkolis</surname><given-names>DP</given-names></name>
<name><surname>Rimm</surname><given-names>DL</given-names></name>
<name><surname>Elefteriades</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections</article-title>. <source>Ann Thorac Surg</source>. <year>2004</year>;<volume>78</volume>:<fpage>2106</fpage>-<lpage>2111</lpage>.</citation>
</ref>
<ref id="bibr26-1066896912440820">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayranpaa</surname><given-names>MI</given-names></name>
<name><surname>Trosien</surname><given-names>JA</given-names></name>
<name><surname>Fontaine</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms</article-title>. <source>J Vasc Surg</source>. <year>2009</year>;<volume>50</volume>:<fpage>388</fpage>-<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr27-1066896912440820">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirsch</surname><given-names>EW</given-names></name>
<name><surname>Radu</surname><given-names>NC</given-names></name>
<name><surname>Allaire</surname><given-names>E</given-names></name>
<name><surname>Loisance</surname><given-names>DY</given-names></name>
</person-group>. <article-title>Pathobiology of idiopathic ascending aortic aneurysms</article-title>. <source>Asian Cardiovasc Thorac Ann</source>. <year>2006</year>;<volume>14</volume>:<fpage>254</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr28-1066896912440820">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>RW</given-names></name>
<name><surname>Geraghty</surname><given-names>PJ</given-names></name>
<name><surname>Lee</surname><given-names>JK</given-names></name>
</person-group>. <article-title>Abdominal aortic aneurysms: basic mechanisms and clinical implications</article-title>. <source>Curr Probl Surg</source>. <year>2002</year>;<volume>39</volume>:<fpage>110</fpage>-<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr29-1066896912440820">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ailawadi</surname><given-names>G</given-names></name>
<name><surname>Eliason</surname><given-names>JL</given-names></name>
<name><surname>Upchurch</surname><given-names>GR</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>Current concepts in the pathogenesis of abdominal aortic aneurysm</article-title>. <source>J Vasc Surg</source>. <year>2003</year>;<volume>38</volume>:<fpage>584</fpage>-<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr30-1066896912440820">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>The pathobiology of aortic aneurysms</article-title>. <source>J Surg Res</source>. <year>2004</year>;<volume>117</volume>:<fpage>163</fpage>-<lpage>175</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>